Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include ...

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimodRHO data show efgartigimod achieved sustained reduction in ...

According to a EULAR press release, the data “suggest the potential for CAR T-cell therapy and other B-cell depleting therapies to reset the immune system in multiple RMD, allowing patients to ...

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthritis and axial spondyloarthritis. The results, presented ...

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The first-in-class biologic, designed as a non-addictive pain treatment, showed ...

Among patients with psoriasis, arthralgia should be considered a risk factor predicting progression to psoriatic arthritis, according to new EULAR points to consider for suspicious features in ...